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ABSTRACT 
Introduction 
Clinical decision support (CDS) displayed in electronic health records (EHRs) has been found to 
reduce the incidence of medication errors and adverse drug events (ADEs). Recent data 
suggested that medication-related CDS alerts were frequently overridden, often inappropriately. 
Patients in the intensive care unit (ICU) are at an increased risk of ADEs; however, limited data 
exist on the benefits of CDS in the ICU. This study aims to evaluate potential harm associated 
with medication-related CDS overrides in the ICU. 
 
Methods 
This was a prospective observational study of adults admitted to any of 6 ICUs between July 
2016 and April 2017 at our institution. Patients with provider-overridden CDS for dose (orders 
for scheduled frequency and not pro re nata), drug-allergy, drug-drug interaction, geriatric, and 
renal alerts (contraindicated medications for renal function or renal dosing) were included. The 
primary outcome was the appropriateness of overrides, which were evaluated by two 
independent reviewers. Secondary outcomes included incidence of ADEs following alert 
override and risk of ADEs based on override appropriateness.  
Results 
A total of 2448 overridden alerts from 712 unique patient encounters met inclusion criteria. The 
overall appropriateness rate for overrides was 81.6% and varied by alert type. More ADEs 
(potential and definite) were identified following inappropriate overrides compared to 
appropriate overrides (16.5 vs. 2.74 per 100 overridden alerts, Fisher’s exact test p <0.001). An 
adjusted logistic regression model showed that inappropriate overrides were associated with an 
increased risk of ADEs (OR 6.14, 95% CI 4.63-7.71, p<0.001).  
Conclusions 
Approximately four of five identified CDS overrides were appropriately overridden, with the rate 
varying by alert type. However, inappropriate overrides were six times as likely to be associated 
with potential and definite ADEs, compared to appropriate overrides. Further efforts should be 
targeted at improving the positive predictive value of CDS such as by suppressing alerts that are 
appropriately overridden. 
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INTRODUCTION 
Adverse drug events (ADEs) are injuries resulting from a medication, which may result 
from medication errors. Given their association with increased hospital length of stay, costs, and 
morbidity and mortality, efforts have been made to reduce these often preventable events.[1-3] 
Medication-related clinical decision support (CDS) has been identified as an effective way to 
reduce medication errors, along with the introduction of computerized provider order entry.[4,5] 
However, literature regarding the proportion of CDS alerts that are overridden including those 
that are overridden inappropriately is increasing.[6,7] Therefore, studies evaluating the 
association between appropriateness of CDS overrides and ADEs are needed, though relatively 
few have been done.[8]  
One patient population that is particularly susceptible to ADEs is intensive care unit 
(ICU) patients, who are at increased risk compared to other hospitalized patients because they 
receive a large number of medications, including many high-risk medications; have altered 
pharmacokinetics and organ systems; and a relatively increased length of stay.[9-11] Two 
prospective cohort studies identifying ADEs in the ICU found that they were relatively common 
(30.6 – 96.5 per 1,000 patient days), and associated with increased morbidity.[12,13] A study 
performed at our institution using our legacy, homegrown electronic health record (EHR) system 
found that inappropriately overridden CDS alerts were associated with an increased risk of 
ADEs.[8] However, this study had limitations including that it was retrospective, had a small 
sample size, and there were concerns about generalizability as it was done within a homegrown 
system. Given the lack of published data regarding harms associated with medication-related 
CDS overrides and the potential increased risk in ICU patients, our objective was to characterize 
these issues in a commercial EHR. By identifying the extent of harm associated with these CDS 
alert overrides, we will identify ways to improve current CDS alert systems, allowing providers 
to focus their attention on clinically pertinent alerts.  
MATERIALS AND METHODS 
We performed a prospective, observational study evaluating medication-related CDS 
alert overrides by providers (anesthesiologist, fellow, nurse practitioner, physician, physician 
assistant, resident). Alert overrides were generated between July 2016 and April 2017 from 
patients admitted to one of the following ICUs at Brigham and Women’s Hospital: medical 
(n=2), neurology (n=2) or surgical (n=2). Alert logic was sourced from First Databank (First 
Databank, South San Francisco, CA, USA). Clinical decision support also included order 
sentences and default doses, although these were inconsistent across medications in regards to 
their function and clinical utility.  
Five computerized alert types that are frequent and of clinical significance in the ICU 
patient population were included: dose, drug-allergy, drug-drug interaction (DDI), geriatric and 
renal. Specific alerts targeted within each alert type were based on a 6-month pilot study 
(October 2015 to May 2016) evaluating alert overrides. Factors considered in choosing the alerts 
to evaluate included clinical experience, frequency, and severity of harm. Further details on the 
specific alerts chosen may be found in the Supplementary File (Appendix A). All alerts that were 
evaluated in this study were presented to providers at the time of order signing (i.e., not 
informational) and required an action by the provider to continue with the order (i.e., override). 
Therefore, the inclusion criteria for this study were 1) Patient was admitted to one of 6 ICUs 
within our institution; 2) The alert was one of five alert types and was in one of the 
subcategories, found in Appendix A; 3) The alert fired on a patient within our study time period 
(July 2016 to April 2017); and 4) The alert was presented to the provider at the time of order 
signing. For geriatric alerts, only ‘contraindicated’ alerts were included as only these were 
provided to multiple providers (i.e., not only the initial ordering provider). Geriatric ‘precaution’ 
alerts were only presented to the ordering provider and were therefore, excluded. Exclusion 
criteria included patients with a hospital length of stay of <24 hours after the override to allow 
for adequate time to evaluate potential harm.  
Data collection included the patient’s age and gender, Sequential Organ Failure 
Assessment score at the time of the patient’s first override included in this study, the type of 
hospital and ICU admission, type of ICU, hospital and ICU length of stay, and documented 
rationale for override.[14] Acute kidney injury was defined using guidelines.[15] The primary 
outcome was the appropriateness of the override, assessed by two independent reviewers with a 
set of predetermined criteria specific for each type of alert. Secondary outcomes included the 
documented reason for override (which was only required for drug-allergy alerts), the incidence 
of ADEs following alert override and association of override appropriateness with ADE. This 
study was approved by the Partners Healthcare Institutional Review Board. 
Appropriateness Evaluation  
Criteria for appropriateness were created using previously published data, including 
guidelines as well as clinical experience of a multidisciplinary group.[13,16] Criteria were 
specific for alert categories and modified until a consensus was reached. Parameters included if 
the medication was being used for comfort measures only (i.e, hospice), gender and baseline 
QTc (defined as value prior to initiation of medications from alert), past receipt of medication 
and documented reactions (if present), if the medication was a home medication and no 
documented adverse reactions had occurred from its use. For patients administered medications 
for comfort measures, these overrides were identified as appropriate if they were used at 
reasonable doses. An example of our appropriateness criteria for geriatric alerts may be found in 
the Supplementary File (Appendix B). Appropriateness was independently evaluated for all 
overridden alerts by two clinical pharmacists (one with significant experience in critical care and 
medication safety, one with significant experience in medication safety). The inter-rater 
agreement for appropriateness was determined with a Cohen’s κ statistic. Disagreements were 
resolved by discussions between the two independent reviewers. If consensus was not achieved, 
a third experienced reviewer (physician with significant experience in medication and patient 
safety) was consulted.  
ADE Evaluation 
To evaluate for ADEs, we performed patient chart reviews on overrides in which the 
patient received the overridden alert’s specific medication(s). An ADE was defined as an injury 
occurring from use of a medication. An ADE included instances where the patient’s corrected 
QT was greater than 500 msec. The period of evaluation started after the override and continued 
for the time that the medication(s) remained active in the patient’s medication orders, which 
could have persisted to hospital discharge in some cases. ADEs that were included were specific 
to the overridden alert. Data relevant to an ADE, such as laboratory reports, medication orders 
and patient notes documented by nurses or providers, were abstracted and summarized by one 
reviewer. These data were blinded (i.e., appropriateness of override was not provided) and 
forwarded to two independent reviewers to determine the likelihood (no ADE, possible ADE, 
definite ADE) and severity of the ADE, regardless of likelihood (significant, serious, life-
threatening). A definite ADE was defined as harm that only could have occurred due to use of 
the medication, while a possible ADE was an ADE which could have resulted from other causes 
(e.g., delirium from ICU illness or from medication use). Definitions for severity of the ADE 
were based on previous work by members of our study team.[11] An example of a life-
threatening ADE was the requirement for cardiopulmonary resuscitation to sustain life, while a 
serious ADE was excessive sedation. If consensus was not achieved, a third experienced 
reviewer (physician) was consulted. Study personnel had undergone training based on guidance 
developed by the Brigham and Women’s Center for Patient Safety Research and Practice, which 
has been used in previous studies and previously described.[17]  
Statistical Analysis 
Descriptive statistics were used to summarize patient characteristics. Fisher’s exact test 
was used to compare categorical variables (rate of override by alert type, appropriateness of 
overrides by alert type and rate of ADEs by appropriateness). Multivariable logistic regression 
was performed to assess the association between the appropriateness of an override and the risk 
of ADEs (possible and definite). The model was adjusted for the following predefined patient 
baseline characteristics: age, gender, Sequential Organ Function Assessment (SOFA) score, 
which may be potential confounders for ADEs. These confounders were chosen based on our 
expert knowledge. A post hoc multivariable linear regression was performed to assess the 
association between the appropriateness of an override and the ICU length of stay. This model 
was also adjusted for potential confounders, as above. A p-value of <0.05 was considered 
significant. Statistical analysis was completed using R 3.3.3 (R Core Team, Vienna, Austria). 
RESULTS 
 A total of 24231 alerts in the parent alert types (dose, drug-allergy, DDI, geriatric, renal) 
were presented to staff from 3312 unique patient encounters, with an overall override rate of 
88.5%. The override rate varied by alert type (dose: 96.8%, drug-allergy: 83.6%, DDI: 91.9%, 
geriatric: 2.3%, renal: 97.1%; p<0.001). For this study, 2448 overridden alerts met inclusion 
criteria (10.1% of total alerts). Patient demographics of unique patient encounters with alerts that 
met inclusion criteria (n=712) are detailed in Table 1.  
Table 1. Patient demographics 
Mean age, y (SD) 62.4 (16.8) 
Female, n (%) 361 (50.7) 
Hospital admission type, n (%) 
   Medical 547 (76.8) 
   Surgical 165 (23.2) 
ICU admission type, n (%) 
   Medical 520 (73.0) 
   Surgical 192 (27.0) 
Initial ICU admitted to, n (%) 
   Medical 368 (51.7) 
   Neurology 146 (20.5) 
   Surgical 198 (27.8) 
Median SOFA, (IQR) 4 (3, 7) 
Median ICU LOS, d (IQR) 3.9 (2.1, 8.8) 
Median hospital LOS, d (IQR) 11.2 (5.4, 20.4) 
Deceased, n (%) 157 (22.1) 
ICU = intensive care unit; IQR = interquartile range; LOS = length of stay; SD = standard deviation 
 
Characteristics of Alert Types 
For drug-allergy overrides, most were due to a definite match between the ordered 
medication and documented allergen (n=248, 89.5%). The most common override was due to 
acetaminophen for the definite match overrides (n=99, 39.9%). Of these overrides, only 10 
(10.1%) were due to an acetaminophen-only allergy, while the remainder was due to documented 
allergies of acetaminophen in combination with other medications (e.g., oxycodone). Of the 29 
potentially life-threatening drug-allergy overrides, anaphylaxis was the most common 
documented reaction to the allergen (n=13, 44.8%). Acetaminophen was again the most common 
medication ordered (n=10, 34.5%), with these overrides due to a documented allergy of a 
combination of acetaminophen with other medications. The most commonly documented 
override reason was ‘Will monitor’ (n=115, 46.4%) and ‘Patient tolerated before’ (n=11, 37.9%) 
for the definite allergy and life-threatening allergy overrides, respectively.  
 The evaluation of DDI overrides showed that most alerts were triggered by medication 
combinations that increase the risk of QTc-prolongation (n=1569, 86.9%), with haloperidol the 
most common medication alerted on (n=716, 39.6%). Subcutaneous heparin (n=18, 50.0%), 
simvastatin (n=22, 34.4%), and sulfamethoxazole-trimethoprim (n=44, 55.7%) were the most 
common medications for the anticoagulant, ‘contraindicated,’ and ‘other’ DDI alert types, 
respectively. A total of 38 patients (2.1%) were continued on home medications that resulted in a 
medication alert. Override reasons were not required and infrequently used (n=504, 27.9%), with 
‘Will monitor’ the most common amongst all DDI overrides (n=342, 67.9%).  
 For the dose alerts, benzodiazepines accounted for most of the overrides (n=31, 75.6%), 
with lorazepam the most common (n=23, 74.2%). Hold parameters, which are input by 
providers, (e.g., medication should not be administered if a parameter such as low blood pressure 
exists) for the medication order were used in only 18 of the alerts (43.9%). ‘Will monitor’ was 
the most common override reason entered (n=8, 66.7%). 
Regarding the geriatric alerts, chlordiazepoxide and nifedipine were the most common 
medications alerted on (n=6 each, 28.6%). ‘Patient tolerated before’ and ‘Will monitor’ were the 
most common override reasons provided (n=3 each, 42.9%).   
 For the renal alerts, electrolytes accounted for most overrides (total: n=154, 50.8%; 
magnesium sulfate: n=24, potassium chloride: n=130). Most alerts were due to acute kidney 
injury (AKI) (n=170, 56.1%), with 88 of these alerts (51.8%) indicative of improving AKI and 3 
alerts in patients undergoing continuous renal replacement therapy. A total of 43 alerts (16.3%) 
were due to continuation of a home medication. Of these alerts, 7 (14.0%) had an increasing 
trend to the patient’s serum creatinine suggestive of developing kidney injury, while 13 (30.2%) 
were in hemodialysis-dependent patients. Of those overrides that had an override reason, ‘Will 
monitor’ was the most commonly documented rationale (n=47, 71.2%).  
Appropriateness of Overrides  
The overall appropriateness rate was 81.6% (Table 2). The κ for the criteria agreement of 
appropriateness was 0.89 (95% CI 0.85-0.93) indicating almost perfect agreement, with a percent 
agreement of 92.1%.  
Table 2. Rate of appropriateness of overrides by alert type 
 Allergy 
(n=277) 
DDI 
(n=1806) 
Dose 
(n=41) 
Geriatric 
(n=21) 
Renal 
(n=303) 
Appropriate, 
n (%) 
231 (83.4) 1481 (82.0) 18 (43.9) 3 (14.3) 265 (87.5) 
DDI = drug-drug interaction 
The appropriateness rate differed significantly by alert type (p<0.001). Evaluation of 
appropriateness rates for the drug-allergy and DDI alert subtypes (Table 3) showed that overrides 
of potentially life-threatening drug-allergy alerts were appropriate approximately 70% of the 
time.  
Table 3. Rate of appropriateness of overrides by alert subtype 
Alert type/subtype Number appropriate, (%) 
Allergy 
   Definite match 221 (89.1) 
   Definite match and life-threatening 20 (69.0) 
DDI 
   Amiodarone-digoxin 58 (100) 
   Anticoagulants  24 (66.7) 
   Contraindicated 40 (62.5) 
   QTc-prolongation 1295 (82.5) 
   Other 64 (81.0) 
DDI = drug-drug interaction 
Appropriateness of DDIs overrides differed significantly between subtypes, with amiodarone-
digoxin overrides always being appropriately overridden.  
Adverse Drug Events 
A total of 1636 overridden alerts resulted in medication administration(s) to the patient 
(66.8% of study sample) and 56 resulted in an ADE (potential or definite) (see Supplementary 
File, Appendix C). The κ for ADE determination was 0.93 (95% CI 0.90-0.96) indicating 
excellent agreement, with a percent agreement of 95.1%. Most ADEs were considered to be 
‘potential’ (n=52, 92.9%). Three out of four ‘definite ADEs’ were a result of a ‘definite’ drug-
allergy match alert such as vancomycin resulting in red-man syndrome. Most ADEs were serious 
(n=50, 89.3%), with altered mental status (n=10, 20.0%) and QTc-prolongation (n=36, 72.0%) 
the most common ADEs encountered. No ADEs resulted from the anticoagulant DDIs. Only one 
ADE resulted from continuation of a home medication (geriatric alert, amitriptyline). 
There was one life-threatening event, potentially an ADE and possibly related to an 
override. This occurred in a patient with a baseline QTc of 535 msec at hospital admission. The 
override was for trazodone (new medication) in conjunction with ritonavir (home medication), 
while the patient was being administered quetiapine (new medication) for agitation. The patient 
suffered a cardiac arrest with ventricular fibrillation and ultimately died a few days later.  
As only medications that were administered to the patient could have been evaluated for 
ADEs, Table 4 details the number of alerts that resulted in medication administration and the rate 
of ADEs by appropriateness of override. Table 4.  
Table 4. Rate of adverse drug events by appropriateness of override  
 
Allergy 
(n=207) 
DDI 
(n=1170) 
Dose 
(n=26) 
Geriatric 
(n=11) 
Renal 
(n=222) 
Total 
(n=1636) 
Appropriate and 
administered, n (%)a 
181 
(87.4) 
959  
(82.0) 
9  
(34.6) 
2  
(18.2) 
209 
(94.1) 
1360 
(83.1) 
Appropriate + ADE, n 
(%)b 
1  
(0.6) 
19  
(2.0) 
1  
(11.1) 
0 0 
21 
(1.5) 
Inappropriate and 
administered, n (%)a 
26  
(12.6) 
211  
(18.0) 
17 
(65.4) 
9  
(81.8) 
13  
(5.9) 
276 
(16.9) 
Inappropriate + ADE, 
n (%)b 
3  
(11.5) 
24  
(11.4) 
3  
(17.6) 
1  
(11.1) 
4  
(30.8) 
35 
(12.7) 
a Percentage based on number of override by alert category 
b Percentage based on number of overrides that resulted in medication administration to the patient 
ADE = adverse drug event; DDI = drug-drug interaction 
 
There was a significant increase in the rate of ADEs with inappropriate overrides, compared to 
appropriate overrides. The unadjusted logistic regression found that inappropriate overrides were 
associated with an increased risk of ADEs (OR 6.13, 95% CI 4.64-7.69, p<0.001), with similar 
findings from the adjusted logistic regression (OR 6.14, 95% CI 4.63-7.71, p<0.001). 
Inappropriate overrides were associated with an increased ICU length of stay by an additional 
2.25 days (95% CI 0.52-3.98, p=0.011). 
DISCUSSION 
We evaluated the appropriateness of medication-related CDS overrides in the ICU and 
ADEs associated with these overrides. A significant proportion of medication-related CDS alerts 
are overridden in the ICU (88.5%). Based on the overrides that were studied, appropriateness 
was also high (81.6%) and varied significantly by the type of alert, with drug-allergy overrides 
being commonly appropriately overridden, whereas geriatric alerts were frequently 
inappropriately overridden. Inappropriate overrides were associated with a six-fold increased risk 
of ADEs (potential and definite), compared to appropriately overridden alerts. Appropriateness 
rates were in line with the published literature, likely due to the alert types studied and the close 
monitoring that occurs in the ICU.[6,13] 
Our institution transitioned from our legacy EHR to a commercial EHR in May 2015. 
Efforts had been continually made to our legacy system to improve available clinical CDS, 
including increasing its positive predictive value (PPV) to limit potential alert fatigue.[18,19] 
With the transition to the commercial EHR, we found a significant increase in alerts by 
approximately 5-fold, along with a significant increase in override rates of certain alert 
types.[20] Potential reasons for this significant increase were the removal of our tailored CDS as 
well as the presentation of CDS alerts at the time of order signing, instead of at the time of 
ordering as in the legacy system. Evaluation of appropriate overrides to modify available EHR 
systems and knowledge bases is of importance to increase the clinical relevance of presented 
CDS alerts. The removal of this tailoring due to our EHR system transition reduced this PPV of 
our CDS alerts.  
Discussion of Specific Alert Types 
 Based on previous experience in evaluating drug-allergy overrides, we focused on two 
specific subtypes that were of particular clinical interest. The appropriateness of the overrides 
differed by the subtype, with definite matches commonly appropriately overridden (89.1%), 
while life-threatening alerts were often appropriately overridden (69.0%) but to a decreased 
extent compared to definite matches. A match between the ordered medication and the 
documented allergen can increase the PPV of these alerts. However, the premise of combination 
products (e.g., oxycodone-acetaminophen) adds complexity to provider documentation of these 
allergies.  
DDIs accounted for the majority of studied CDS overrides, due to a large number of 
QTc-prolonging medication combinations. In evaluating the subtypes of the DDI alerts, the 
amiodarone-digoxin and anticoagulant subtypes were of particular interest. None of the 
amiodarone-digoxin overrides were inappropriate, and no anticoagulant DDIs resulted in ADEs. 
The lack of ADEs associated with anticoagulants, which are considered to be high-risk 
medications, is surprising but was often due to discontinuation of one anticoagulant at the same 
time as ordering another.[21] Our CDS system believed that the to-be-discontinued anticoagulant 
was still an active order, when in fact it was in the process of being discontinued. In evaluating 
the ‘contraindicated’ DDIs, overrides were frequently appropriate as simvastatin and a 
metabolism-inhibitor were the most common DDI combinations, which were often not reflective 
of the dose threshold for simvastatin that is recommended in guidelines.[22] The low rate of 
ADEs associated with this DDI subtype was due to the large number of simvastatin DDIs. It 
would be expected to require more time than a typical ICU stay to occur (i.e., 
myopathy/rhabdomyolysis). 
In evaluating the dose alerts, it was concerning that only 43.9% of these orders had any 
hold parameters associated with the medication. Of the 4 ADEs that potentially resulted from the 
overrides, only 1 had a hold parameter associated with the order.  
For geriatric alerts, an interesting finding was that the acceptance of these alerts (97.5%) 
was much more common than reported in the literature.[8] This acceptance rate was also 
significantly greater than the rest of the studied alert types. Potentially, these alerts are the most 
specific to a patient, resulting in the highest provider acceptance. This is supported by the high 
rate of inappropriate overrides found in this study (85.7%). The small number of overridden 
alerts was because only ‘contraindicated’ alerts were included in this study because they were 
presented to all providers. ‘Precaution’ alerts were only presented to the original ordering 
provider and not to subsequent providers in cases of reordering the same medication or changing 
the dose. The renal alerts contrasted previous findings within our institution, when they had been 
tailored to be as specific as possible.[18] In the commercial database, electrolyte alerts accounted 
for most of the overrides (50.8%), whereas no such alerts were active in our legacy system. 
These were clinically insignificant alerts, resulting in a high rate of appropriate overrides.  
Recommendations to Improve Clinical Decision Support 
One finding that is noted in the results of this study is the evaluation of what CDS alerts 
exist within an institution. Malfunctions of CDS have been studied in the literature, which has 
identified that they may be widespread and may exist for long time periods due to lack of 
investigation into this matter.[23] A few of the malfunctions that were encountered during this 
study period were focused on the actual medication ordered compared to what the CDS believed 
was ordered (e.g., simvastatin as previously mentioned). This illustrates the need for evaluation 
of CDS, especially in the time period immediately following EHR implementation, as we did in 
our institution.  
A general improvement would be linking the override reason to an appropriate 
intervention. For example, when “Will monitor” is chosen as the override reason for an 
amiodarone-digoxin DDI, an order for a serum digoxin level would be made. This could become 
more specific by evaluating additional parameters such as the dose and renal function in 
determining the date and time of the serum digoxin level order.  
Although it may be difficult to determine which component of a combination product 
may lead to an allergy, the use of previous tolerance to a component would likely be able to 
reduce the alert burden. This could be accomplished through the use of machine learning and 
natural language processing that could more accurately determine culprit medications.[24,25] 
Additionally, our EHR and CDS system can differentiate between a true medication allergy and 
that of intolerance. By differentiating how CDS presents a true medication allergy (e.g., 
anaphylaxis) to an intolerance (e.g., nausea), providers may value CDS more (i.e., more correctly 
respond), which in turn may reduce the incidence of inappropriate overrides. For dose alerts, 
incorporation of a hold parameter could potentially prevent ADEs from occurring. Removal of 
renal alerts for one-time orders of electrolytes as long as the serum lab value (within a reasonable 
amount of time) was within a certain range, would help alleviate a significant portion of these 
alerts.[26] 
Limitations 
Our study has several limitations. First, this study was completed at a single center based 
on only one commercial EHR/database and therefore, may not necessarily be applicable to other 
institutions. However, data suggests that this commercial EHR is implemented in a significant 
portion of the market.[27] Second, we may not have exhaustively evaluated factors that the 
provider may have considered in determining the decision to override a CDS alert. Nevertheless, 
we made considerable efforts to evaluate the appropriateness of overrides and subsequent ADEs 
on a case-by-case basis, formulation of criteria using a multidisciplinary expert team, and the use 
of independent adjudicators. Third, we are unable to determine causality of our findings, only 
association, given the nature of our study design. Fourth, we were time limited as we only 
evaluated for ADEs that occurred during the hospital stay. Patient may have remained on some 
medications that were ordered upon hospital discharge, which would be important for ADEs that 
are expected to take a longer time to manifest. Fifth, we were dependent on clinical 
documentation for the determination of ADEs, which might have limited our findings. Finally, 
we included in our definition of an ADE some events (e.g., QTc greater than 500 msec), that 
other studies may not have considered to be an ADE.    
CONCLUSION  
Approximately four of five identified CDS overrides were appropriately overridden, 
though the rate varied substantially by alert type. Inappropriate overrides were six times as likely 
to be associated with an ADE (potential and definite) compared to appropriate overrides, 
confirming that decision support can identify clinically important situations.  Further efforts 
should be targeted at improving the positive predictive value of CDS in a number of ways, 
including by following human factors principles in alert presentation, by suppressing alerts that 
are appropriately overridden, by using clinical information about individual patients to improve 
the likelihood that the alerts will be appropriate, and by using techniques such as artificial 
intelligence to help determine which alerts to present. 
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